Form 10-Q · Quarterly report
Supermicro 10-Q, filed Nov 6, 2026
- Filed
- CIK
- 0001375365
- Accession no.
- 0001375365-26-000027
Summary
Supermicro reported net sales of $19.95 billion for the quarter ended September 30, 2026, up 297.5% from $5.02 billion a year earlier, and net income of $1.59 billion versus $168.3 million, which it attributed primarily to increased demand for AI platforms. Gross margin rose to 12.7% from 9.3% on a change in product and customer mix, while operating expenses increased 67.1%.
Key points
- Diluted net income per common share was $1.75 for the quarter ended September 30, 2026, compared with $0.26 a year earlier.
- Operating expenses rose 67.1% year over year, driven by higher headcount, salary and stock-based compensation, and product development costs.
- Purchases from related-party contract manufacturers Ablecom and Compuware combined represented 1.1% of cost of sales, down from 3.4% a year earlier.
- Supermicro said it monitors product introduction cycles at NVIDIA, Intel, AMD, Broadcom, Samsung and Micron to time its own releases, and is expanding its Data Center Building Block Solutions for AI and data center customers.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview We are a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, we are committed to delivering first-to-market innovation for Enterprise, Cloud, artificial intelligence (“AI”), and 5G Telco/Edge IT Infrastructure. As a Total IT Solutions manufacturer, our offerings include server, AI systems, storage, IoT devices, switches, software, and support services. Supermicro's expertise in motherboard, power, and chassis design drives our ability to develop and produce next-generation innovations, from cloud to edge, for our global customers. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.